{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:15:57Z","timestamp":1790471757411,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ymthe.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T02:39:21Z","timestamp":1518057561000},"page":"947-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic"],"prefix":"10.1016","volume":"26","author":[{"given":"Jana","family":"Miniarikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin M.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Konstantinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.02.002_bib1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of huntington\u2019s disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.ymthe.2018.02.002_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.25717","article-title":"Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk","volume":"29","author":"Fisher","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"Macdonald","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib5","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2018.02.002_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib8","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/mds.26001","article-title":"Genetic modifiers of Huntington\u2019s disease","volume":"29","author":"Gusella","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12035-015-9662-8","article-title":"Huntington\u2019s disease: relationship between phenotype and genotype","volume":"54","author":"Sun","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2018.02.002_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/hmg\/ddi071","article-title":"A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure","volume":"14","author":"Poirier","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib13","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2018.02.002_bib14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","article-title":"Mouse models of Huntington\u2019s disease and methodological considerations for therapeutic trials","volume":"1792","author":"Ferrante","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2018.02.002_bib15","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1523\/JNEUROSCI.22-09-03473.2002","article-title":"Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length","volume":"22","author":"de Almeida","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"S\u00e1nchez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.02.002_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrn2786","article-title":"Prion-like mechanisms in neurodegenerative diseases","volume":"11","author":"Frost","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","article-title":"Human-to-mouse prion-like propagation of mutant huntingtin protein","volume":"132","author":"Jeon","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.24174","article-title":"Mutant huntingtin is present in neuronal grafts in Huntington disease patients","volume":"76","author":"Cicchetti","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","article-title":"Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.ymthe.2018.02.002_bib22","doi-asserted-by":"crossref","first-page":"12784","DOI":"10.1073\/pnas.221451398","article-title":"Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington\u2019s disease brains, associate with membranes, and undergo calpain-dependent proteolysis","volume":"98","author":"Kim","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/brain\/awp006","article-title":"Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin","volume":"132","author":"Pouladi","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2018.02.002_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1523\/JNEUROSCI.1305-11.2012","article-title":"Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin","volume":"32","author":"Waldron-Roby","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib25","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1523\/JNEUROSCI.22-18-07862.2002","article-title":"Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington\u2019s disease","volume":"22","author":"Wellington","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib26","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.neuron.2015.10.038","article-title":"RAN translation in Huntington disease","volume":"88","author":"Ba\u00f1ez-Coronel","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2018.02.002_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2014.11.022","article-title":"Huntington\u2019s disease: an update of therapeutic strategies","volume":"556","author":"Kumar","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2018.02.002_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11910-017-0711-8","article-title":"Huntington disease: linking pathogenesis to the development of experimental therapeutics","volume":"17","author":"Mestre","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ymthe.2018.02.002_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/326194a0","article-title":"Homozygotes for Huntington\u2019s disease","volume":"326","author":"Wexler","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.02.002_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","article-title":"CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup","volume":"84","author":"Warby","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib34","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/mt.2015.128","article-title":"Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry","volume":"23","author":"Kay","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cge.12385","article-title":"Personalized gene silencing therapeutics for Huntington disease","volume":"86","author":"Kay","year":"2014","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib36","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib37","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib39","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington\u2019s disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2018.02.002_bib40","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","article-title":"Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia","volume":"25","author":"Keiser","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib41","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","article-title":"Oligonucleotide therapeutic approaches for Huntington disease","volume":"121","author":"Sah","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.02.002_bib42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"R1","key":"10.1016\/j.ymthe.2018.02.002_bib43","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1093\/hmg\/ddr137","article-title":"RNAi medicine for the brain: progresses and challenges","volume":"20","author":"Boudreau","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","article-title":"Choosing an animal model for the study of Huntington\u2019s disease","volume":"14","author":"Pouladi","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib45","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/mds.26008","article-title":"Mind the gap: models in multiple species needed for therapeutic development in Huntington\u2019s disease","volume":"29","author":"Howland","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib46","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/mds.26010","article-title":"Preclinical models: needed in translation? A pro\/con debate","volume":"29","author":"Philips","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib48","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1093\/nar\/gku385","article-title":"Oligonucleotide-based strategies to combat polyglutamine diseases","volume":"42","author":"Fiszer","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2018.02.002_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.14304\/SURYA.JPR.V4N7.5","article-title":"RNA therapeutics: RNAi and antisense mechanisms and clinical applications","volume":"4","author":"Chery","year":"2016","journal-title":"Postdoc J."},{"key":"10.1016\/j.ymthe.2018.02.002_bib50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2018.02.002_bib51","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","article-title":"Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases","volume":"18","author":"Southwell","year":"2012","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2018.02.002_bib52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/nat.2013.0452","article-title":"Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification","volume":"24","author":"Evers","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib53","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In\u00a0vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib54","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"\u00d8stergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2018.02.002_bib55","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib56","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm.3514","article-title":"Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington\u2019s disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2018.02.002_bib57","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2018.02.002_bib58","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","article-title":"Widespread suppression of huntingtin with convection-enhanced delivery of siRNA","volume":"233","author":"Stiles","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib59","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1038\/mtna.2015.20","article-title":"Onset time and durability of huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA","volume":"4","author":"Grondin","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2018.02.002_bib60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib61","first-page":"434","article-title":"In\u00a0vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs","volume":"7","author":"Borel","year":"2011","journal-title":"J.\u00a0RNAi Gene Silencing"},{"key":"10.1016\/j.ymthe.2018.02.002_bib62","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1089\/hum.2011.035","article-title":"Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines","volume":"22","author":"Bish","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib63","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.02.002_bib64","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800149-3.00002-0","article-title":"Clinical applications involving CNS gene transfer","volume":"87","author":"Kantor","year":"2014","journal-title":"Adv. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-12-800149-3.00003-2","article-title":"Methods for gene transfer to the central nervous system","volume":"87","author":"Kantor","year":"2014","journal-title":"Adv. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib67","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/1566523211313030006","article-title":"Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis","volume":"13","author":"Knight","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib68","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-associated virus-based gene therapy for CNS diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib69","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","article-title":"Delivering a disease-modifying treatment for Huntington\u2019s disease","volume":"20","author":"Godinho","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2018.02.002_bib71","doi-asserted-by":"crossref","first-page":"e99341","DOI":"10.1371\/journal.pone.0099341","article-title":"Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells","volume":"9","author":"Drouet","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2018.02.002_bib72","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib73","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2018.02.002_bib74","article-title":"Artificial miRNAs reduce human mutant Huntingtin throughout the striatum in a transgenic sheep model of Huntington\u2019s disease","author":"Pfister","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib75","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.26006","article-title":"Animal models of Huntington\u2019s disease for translation to the clinic: best practices","volume":"29","author":"Menalled","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib76","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1172\/JCI45364","article-title":"The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease","volume":"121","author":"Munoz-Sanjuan","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.02.002_bib77","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/mds.26021","article-title":"Clinical trials in Huntington\u2019s disease: interventions in early clinical development and newer methodological approaches","volume":"29","author":"Sampaio","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib78","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ilar.48.4.356","article-title":"Animal models of Huntington\u2019s disease","volume":"48","author":"Ramaswamy","year":"2007","journal-title":"ILAR J."},{"key":"10.1016\/j.ymthe.2018.02.002_bib79","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.nbd.2008.10.009","article-title":"CAG repeat lengths > or\u00a0=335 attenuate the phenotype in the R6\/2 Huntington\u2019s disease transgenic mouse","volume":"33","author":"Dragatsis","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib81","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington\u2019s disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib82","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1073\/pnas.0800048105","article-title":"DNA instability in postmitotic neurons","volume":"105","author":"Gonitel","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib84","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington\u2019s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2018.02.002_bib85","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib86","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib87","first-page":"1115","article-title":"A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles","volume":"26","author":"Southwell","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/hmg\/dds397","article-title":"A fully humanized transgenic mouse model of Huntington disease","volume":"22","author":"Southwell","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib89","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1523\/JNEUROSCI.22-18-08266.2002","article-title":"Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington\u2019s disease knock-in mice","volume":"22","author":"Menalled","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib91","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1602\/neurorx.2.3.465","article-title":"Knock-in mouse models of Huntington\u2019s disease","volume":"2","author":"Menalled","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.ymthe.2018.02.002_bib92","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/hmg\/ddg075","article-title":"Transgenic rat model of Huntington\u2019s disease","volume":"12","author":"von H\u00f6rsten","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib93","doi-asserted-by":"crossref","first-page":"15426","DOI":"10.1523\/JNEUROSCI.1148-12.2012","article-title":"A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease","volume":"32","author":"Yu-Taeger","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib94","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00335-017-9687-6","article-title":"Bridging the gap: large animal models in neurodegenerative research","volume":"28","author":"Eaton","year":"2017","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.ymthe.2018.02.002_bib95","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/hmg\/ddq063","article-title":"An ovine transgenic Huntington\u2019s disease model","volume":"19","author":"Jacobsen","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JHD-130001","article-title":"A transgenic minipig model of Huntington\u2019s disease","volume":"2","author":"Baxa","year":"2013","journal-title":"J.\u00a0Huntingtons Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib97","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/hmg\/ddq159","article-title":"Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases","volume":"19","author":"Marchetto","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib99","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","article-title":"Disease-specific induced pluripotent stem cells","volume":"134","author":"Park","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3233\/JHD-160199","article-title":"Induced pluripotent stem cells in Huntington\u2019s disease research: progress and opportunity","volume":"5","author":"Tousley","year":"2016","journal-title":"J.\u00a0Huntingtons Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib101","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/stem.1135","article-title":"Neuronal properties, in\u00a0vivo effects, and pathology of a Huntington\u2019s disease patient-derived induced pluripotent stem cells","volume":"30","author":"Jeon","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2018.02.002_bib102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-016-0092-5","article-title":"Manifestation of Huntington\u2019s disease pathology in human induced pluripotent stem cell-derived neurons","volume":"11","author":"Nekrasov","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2018.02.002_bib103","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5500\/wjt.v5.i4.209","article-title":"Induced pluripotent stem cells for modeling neurological disorders","volume":"5","author":"Russo","year":"2015","journal-title":"World J. Transplant."},{"key":"10.1016\/j.ymthe.2018.02.002_bib104","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.omtm.2017.05.001","article-title":"Preclinical evaluation of a lentiviral vector for huntingtin silencing","volume":"5","author":"Cambon","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2018.02.002_bib105","first-page":"55","article-title":"The Libechov minipig as a large animal model for preclinical research in Huntington\u2019s disease - thoughts and perspectives","volume":"78","author":"Schramke","year":"2017","journal-title":"Cesk. Slov. Neurol. N."},{"key":"10.1016\/j.ymthe.2018.02.002_bib106","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1073858414521870","article-title":"Adeno-associated virus vectors and neurological gene therapy","volume":"21","author":"Ojala","year":"2015","journal-title":"Neuroscientist"},{"key":"10.1016\/j.ymthe.2018.02.002_bib107","doi-asserted-by":"crossref","first-page":"e76310","DOI":"10.1371\/journal.pone.0076310","article-title":"Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain","volume":"8","author":"Aschauer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2018.02.002_bib108","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fnana.2016.00128","article-title":"Perspective on the road toward gene therapy for Parkinson\u2019s disease","volume":"10","author":"Blits","year":"2017","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymthe.2018.02.002_bib109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib110","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/mtm.2016.37","article-title":"Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington\u2019s disease","volume":"3","author":"Hadaczek","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2018.02.002_bib111","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib112","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib113","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-017-1200-1","article-title":"Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models","volume":"15","author":"Markusic","year":"2017","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2018.02.002_bib114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/humc.2015.002","article-title":"A review of gene therapy in canine and feline models of lysosomal storage disorders","volume":"26","author":"Bradbury","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2018.02.002_bib115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/hum.2017.026","article-title":"Evaluation of intrathecal routes of administration for adeno-associated virus vectors in large animals","volume":"29","author":"Hinderer","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2009.07.029","article-title":"The role of the blood-CNS barrier in CNS disorders and their treatment","volume":"37","author":"Palmer","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib118","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib119","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","article-title":"Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain","volume":"665","author":"Matsuzaki","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2018.02.002_bib121","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2009.286","article-title":"Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain","volume":"18","author":"Markakis","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib122","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib123","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/gt.2011.130","article-title":"Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs","volume":"19","author":"Federici","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib124","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.97.7.3428","article-title":"Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system","volume":"97","author":"Davidson","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib126","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1124\/jpet.109.165399","article-title":"Intrathecal delivery of a mutant micro-opioid receptor activated by naloxone as a possible antinociceptive paradigm","volume":"334","author":"Kao","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib127","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fnana.2014.00066","article-title":"Supraspinal gene transfer by intrathecal adeno-associated virus serotype 5","volume":"8","author":"Schuster","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymthe.2018.02.002_bib128","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","article-title":"Treating the whole body in Huntington\u2019s disease","volume":"14","author":"Carroll","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib129","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","article-title":"Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients","volume":"80","author":"Bartus","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2018.02.002_bib130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib131","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.02.002_bib132","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1239","article-title":"A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease","volume":"11","author":"Tuszynski","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2018.02.002_bib133","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib134","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/mds.26426","article-title":"Trophic factors for Parkinson\u2019s disease: to live or let die","volume":"30","author":"Olanow","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib135","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.02.002_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci6030038","article-title":"Deep brain stimulation in Huntington\u2019s disease-preliminary evidence on pathophysiology, efficacy and safety","volume":"6","author":"Wojtecki","year":"2016","journal-title":"Brain Sci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib137","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s13311-017-0520-4","article-title":"Convection-enhanced delivery","volume":"14","author":"Mehta","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2018.02.002_bib138","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/1570159X14666160614093615","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment","volume":"15","author":"Zhou","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib139","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3171\/jns.2005.103.5.0923","article-title":"Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents","volume":"103","author":"Krauze","year":"2005","journal-title":"J.\u00a0Neurosurg."},{"key":"10.1016\/j.ymthe.2018.02.002_bib140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jneumeth.2010.10.010","article-title":"Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain","volume":"194","author":"Carty","year":"2010","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.ymthe.2018.02.002_bib141","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1073\/pnas.0810682106","article-title":"Efficient gene therapy-based method for the delivery of therapeutics to primate cortex","volume":"106","author":"Kells","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib142","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2018.02.002_bib143","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/gt.2012.27","article-title":"Axonal transport of adeno-associated viral vectors is serotype-dependent","volume":"20","author":"Salegio","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib144","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1038\/mtna.2015.7","article-title":"Artificial miRNAs targeting mutant huntingtin show preferential silencing in\u00a0vitro and in\u00a0vivo","volume":"4","author":"Monteys","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2018.02.002_bib145","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","article-title":"AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease","volume":"16","author":"Franich","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib146","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib147","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib148","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fnmol.2014.00076","article-title":"Biology of adeno-associated viral vectors in the central nervous system","volume":"7","author":"Murlidharan","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib149","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fnins.2016.00193","article-title":"The enemy within: innate surveillance-mediated cell death, the common mechanism of neurodegenerative disease","volume":"10","author":"Richards","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib150","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bj\u00f6rkqvist","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2018.02.002_bib151","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/glia.20526","article-title":"Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington\u2019s disease","volume":"55","author":"Simmons","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2018.02.002_bib152","doi-asserted-by":"crossref","first-page":"8653132","DOI":"10.1155\/2016\/8653132","article-title":"Neuroimmunology of Huntington\u2019s disease: revisiting evidence from human studies","volume":"2016","author":"Rocha","year":"2016","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ymthe.2018.02.002_bib153","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nn.3668","article-title":"Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining\u00a0factors","volume":"17","author":"Crotti","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib154","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2011.09.003","article-title":"Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease","volume":"45","author":"Franciosi","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2016.02.012","article-title":"Revelation of the IFN\u03b1, IL-10, IL-8 and IL-1\u03b2 as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington\u2019s disease model","volume":"293","author":"Valekova","year":"2016","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2018.02.002_bib156","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1002\/jgm.506","article-title":"Recombinant AAV-mediated gene delivery to the central nervous system","volume":"6","author":"Tenenbaum","year":"2004","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2018.02.002_bib157","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.02.002_bib158","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mcn.2016.10.007","article-title":"Systemic application of AAV vectors targeting GFAP-expressing astrocytes in Z-Q175-KI Huntington\u2019s disease mice","volume":"77","author":"Vagner","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib159","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2018.02.002_bib160","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1007\/s11095-011-0608-1","article-title":"Subcellular fate and off-target effects of siRNA, shRNA, and miRNA","volume":"28","author":"Singh","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2018.02.002_bib161","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nmeth913","article-title":"Enhancing and confirming the specificity of RNAi experiments","volume":"3","author":"Cullen","year":"2006","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2018.02.002_bib162","doi-asserted-by":"crossref","first-page":"13315","DOI":"10.1093\/nar\/gku979","article-title":"Single nucleotide seed modification restores in\u00a0vivo tolerability of a toxic artificial miRNA sequence in the mouse brain","volume":"42","author":"Monteys","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2018.02.002_bib163","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib164","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1472-6750-12-42","article-title":"Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100","volume":"12","author":"Maczuga","year":"2012","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib165","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cell.2012.09.042","article-title":"The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in\u00a0vivo","volume":"151","author":"Gu","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib166","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1261\/rna.043950.113","article-title":"Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity","volume":"20","author":"Herrera-Carrillo","year":"2014","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib167","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1038\/mtna.2014.27","article-title":"Designing Ago2-specific siRNA\/shRNA to avoid competition with endogenous miRNAs","volume":"3","author":"Ma","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2018.02.002_bib168","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymthe.2018.02.002_bib169","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1073\/pnas.1524575113","article-title":"Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.02.002_bib170","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.02.002_bib171","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2018.02.002_bib172","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02257483","article-title":"Structure and expression of the Huntington\u2019s disease gene: evidence against simple inactivation due to an expanded CAG repeat","volume":"20","author":"Ambrose","year":"1994","journal-title":"Somat. Cell Mol. Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib173","doi-asserted-by":"crossref","first-page":"e1006083","DOI":"10.1371\/journal.pgen.1006083","article-title":"N-terminal huntingtin knock-in mice: implications of removing the N-terminal region of huntingtin for therapy","volume":"12","author":"Liu","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymthe.2018.02.002_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170235","article-title":"Is huntingtin dispensable in the adult brain?","volume":"6","author":"Liu","year":"2017","journal-title":"J.\u00a0Huntingtons Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib175","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib176","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/psp4.12097","article-title":"Modeling variability in the progression of Huntington\u2019s disease a novel modeling approach applied to structural imaging markers from TRACK-HD","volume":"5","author":"Warner","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib177","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study","volume":"16","author":"Hensman Moss","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib178","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/mds.26364","article-title":"Multivariate prediction of motor diagnosis in Huntington\u2019s disease: 12 years of PREDICT-HD","volume":"30","author":"Long","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib179","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnagi.2014.00078","article-title":"Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study","volume":"6","author":"Paulsen","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ymthe.2018.02.002_bib180","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mds.26118","article-title":"A longitudinal study of magnetic resonance spectroscopy Huntington\u2019s disease biomarkers","volume":"30","author":"Sturrock","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib181","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JHD-170236","article-title":"Dynamic prediction of motor diagnosis in Huntington\u2019s disease using a joint modeling approach","volume":"6","author":"Li","year":"2017","journal-title":"J.\u00a0Huntingtons Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib182","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/WNL.0b013e3181fc27e4","article-title":"Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease","volume":"75","author":"Sturrock","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2018.02.002_bib183","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mds.25010","article-title":"Brain metabolite alterations and cognitive dysfunction in early Huntington\u2019s disease","volume":"27","author":"Unschuld","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2018.02.002_bib184","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/archneurol.2011.2945","article-title":"Alterations in brain transition metals in Huntington disease: an evolving and intricate story","volume":"69","author":"Rosas","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3988\/jcn.2013.9.1.21","article-title":"Decreased metabolism in the cerebral cortex in early-stage Huntington\u2019s disease: a possible biomarker of disease progression?","volume":"9","author":"Shin","year":"2013","journal-title":"J.\u00a0Clin. Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib186","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1172\/JCI69411","article-title":"Metabolic network as a progression biomarker of premanifest Huntington\u2019s disease","volume":"123","author":"Tang","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.02.002_bib187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-160196","article-title":"Cerebrospinal fluid biomarkers for Huntington\u2019s disease","volume":"5","author":"Byrne","year":"2016","journal-title":"J.\u00a0Huntingtons Dis."},{"key":"10.1016\/j.ymthe.2018.02.002_bib188","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","article-title":"Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease","volume":"139","author":"Rodrigues","year":"2016","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2018.02.002_bib189","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.02.002_bib190","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1038\/srep12166","article-title":"Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression","volume":"5","author":"Southwell","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2018.02.002_bib191","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib192","doi-asserted-by":"crossref","first-page":"e0163479","DOI":"10.1371\/journal.pone.0163479","article-title":"Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington\u2019s disease","volume":"11","author":"Rodrigues","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2018.02.002_bib193","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/jcbfm.2011.157","article-title":"Cortical metabolites as biomarkers in the R6\/2 model of Huntington\u2019s disease","volume":"32","author":"Zacharoff","year":"2012","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ymthe.2018.02.002_bib194","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fneur.2017.00091","article-title":"Quantitative electroencephalographic biomarkers in preclinical and human studies of Huntington\u2019s disease: are they fit-for-purpose for treatment development?","volume":"8","author":"Leuchter","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2018.02.002_bib195","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5665\/sleep.5448","article-title":"Quantitative electroencephalographic analysis provides an early-stage indicator of disease onset and progression in the zQ175 knock-in mouse model of Huntington\u2019s disease","volume":"39","author":"Fisher","year":"2016","journal-title":"Sleep (Basel)"},{"key":"10.1016\/j.ymthe.2018.02.002_bib196","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.neuroimage.2012.01.141","article-title":"Spatiotemporal mapping of brain atrophy in mouse models of Huntington\u2019s disease using longitudinal in\u00a0vivo magnetic resonance imaging","volume":"60","author":"Aggarwal","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.ymthe.2018.02.002_bib197","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuroimage.2011.02.022","article-title":"Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington\u2019s disease mouse model","volume":"56","author":"Cheng","year":"2011","journal-title":"Neuroimage"},{"key":"10.1016\/j.ymthe.2018.02.002_bib198","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/mp.2015.81","article-title":"Huntington\u2019s disease cerebrospinal fluid seeds aggregation of mutant huntingtin","volume":"20","author":"Tan","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ymthe.2018.02.002_bib199","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JHD-170245","article-title":"Fifteen years of clinical trials in Huntington\u2019s disease: a very low clinical drug development success rate","volume":"6","author":"Travessa","year":"2017","journal-title":"J.\u00a0Huntingtons Dis."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618300558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618300558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:53:44Z","timestamp":1761501224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618300558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":199,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1525001618300558"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.002","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}